Bharat Book

Global Markets for Marine-Derived Pharmaceuticals available through

Press Release   •   Nov 17, 2011 15:41 IST

 * The global market for marine-derived drugs by type was around $4.8 billion in 2011, which is expected to be around $5.3 billion in 2012. This global market is forecasted to reach $8.6 billion by 2016 at a compound annual growth rate (CAGR) of 12.5% for the five year period of 2011 to 2016.
 * The market for sponges was $3 billion in 2010 and is expected to reach around $3.2 billion in the year 2012. BCC has forecasted that this market will reach nearly $4 billion by 2016 at a compound annual growth rate (CAGR) of 5% for a five year period.
 * Mollusc is the fastest growing market and is expected to grow from $69.4 million in 2011 to $490.1 million by 2016 at a CAGR of 47.8%.
 “The search for bioactive metabolites from marine microbes has only just begun”—David Newman, D. Phil, and Russell Hill, PhD, New Drugs from Marine Microbes: The Tide is Turning (2006) market research reports
 BCC’s goal in conducting this study was to determine the current status of the global marine-derived pharmaceutical market, including its growth potential during the period of 2011 to 2016. Our key objective is to present a comprehensive analysis of marine life and technology as they relate to pharmaceutical applications and to forecast this market’s future direction.
 Our understanding of marine life only began during the last half of the 20th century. The first marine discovery that led to a pharmaceutical drug began in the 1950s when chemists Bergmann and Feeney isolated nucleosidic compounds from the Caribbean sponge Cryptotethya crypta. Marine drugs on the market today can be traced to this discovery (e.g., anticancer drug cytarabine).
 While marine life is used for many applications, including food and industrial processing, its use in the pharmaceutical industry has just begun. Marine life offers a complex and diverse genetic resource unavailable on land, which has led to the exploration of the oceans to find new tests and cures for illnesses. Entire classes of antibiotics desperately needed for a world surviving on relatively few antibiotics, which people are becoming resistant to, could be found in just a few marine samples.
 This report describes the potential of marine research and its growth prospects. It is estimated that marine-derived drugs will essentially double in number from 2011 to 2016. Because marine-derived drugs already account for a few powerful drugs, this area of the drug industry has already generated billions of dollars to date.
 The scope of this study encompasses research organizations, the U.S. government chiefly in the form of the National Cancer Institute (NCI), and companies that develop or help in the development process of pharmaceuticals derived from marine life. Included are extensive descriptions, perspectives, and predictive information, including forecasts of growth over the next 5 years. Technological issues, including the latest trends, are discussed.
 In this report, marine-derived pharmaceuticals are described in terms of their history in medicine, technology types and categories, research organizations, major companies, impact on the pharmaceutical market, applications, current market values, growth potential, and significant trends. This study will be of interest to non-profits and the government sector as well as the biotechnology and pharmaceutical industries and related life science, analytics, drug discovery, and diagnostic test manufacturing companies as well as all those interested in or actively working in drug and imaging agent research and investors in all of the above.
 BCC presents an analysis of the types of technologies, applications, and therapeutic areas representing the financial value of marine-derived pharmaceuticals. Estimated values are based on actual aggregate sales for the years discussed. Information, in general, is compiled through a combination of primary and secondary research, including annual reports and interviews with company and government officials as well as experts in academia.
 BCC’s analysis includes the review of more than 50 companies and information from financial and trade publications as well as the U.S. Food and Drug Administration (FDA). Included were pharmaceutical and biotechnology companies as well as support companies to them.
 For more information kindly visit :
 Contact us at :
 Bharat Book Bureau
 Tel: +91 22 27578668 / +91 22 27579438
 Fax: +91 22 27579131
 Follow us on twitter:!/Sandhya3B

Bharat Book Bureau, the leading market research information aggregator provides market research reports, company profiles, country reports, newsletters, and online databases for the past twenty four years to corporate, consulting firms, academic institutions, government departments, agencies etc., globally, including India. Our market research reports help global companies to know different market before starting up business / expanding in different countries across the world.